Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

6/2/25 4:00:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46^th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:

Jamie Constantine

Investor Relations

+1 781 873 2402

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-conference-302471011.html

SOURCE Alkermes plc

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
7/15/2025	$43.00	Buy	Goldman
6/17/2025	$42.00	Neutral → Buy	UBS
5/28/2025	$45.00	Buy	Needham
3/13/2025	$40.00	Sector Perform	RBC Capital Mkts
3/4/2025	$21.00 → $38.00	Sell → Neutral	UBS
2/11/2025	$40.00	Buy	Deutsche Bank
11/5/2024	$25.00 → $36.00	Hold → Buy	Stifel
6/17/2024	$34.00	Buy	TD Cowen

More analyst ratings

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

6/2/25 4:00:00 PM ET

$ALKS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

About Alkermes plc

Alkermes Contact:

Jamie Constantine

Investor Relations

+1 781 873 2402

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-conference-302471011.html

SOURCE Alkermes plc

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
7/15/2025	$43.00	Buy	Goldman
6/17/2025	$42.00	Neutral → Buy	UBS
5/28/2025	$45.00	Buy	Needham
3/13/2025	$40.00	Sector Perform	RBC Capital Mkts
3/4/2025	$21.00 → $38.00	Sell → Neutral	UBS
2/11/2025	$40.00	Buy	Deutsche Bank
11/5/2024	$25.00 → $36.00	Hold → Buy	Stifel
6/17/2024	$34.00	Buy	TD Cowen

More analyst ratings

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALKS

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALKS

$ALKS
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Alkermes plc

SEC Form S-8 filed by Alkermes plc

SEC Form 10-Q filed by Alkermes plc

$ALKS
Insider Trading

EVP, CLO, Alkermes, Inc. Gaffin David Joseph converted options into 2,014 units of Ordinary Shares and covered exercise/tax liability with 895 units of Ordinary Shares, increasing direct ownership by 0.55% to 205,374 units (SEC Form 4)

SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

$ALKS
Press Releases

Alkermes plc Reports Second Quarter 2025 Financial Results

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Alkermes to Report Second Quarter Financial Results on July 29, 2025

$ALKS
Analyst Ratings

Goldman initiated coverage on Alkermes Plc with a new price target

Alkermes Plc upgraded by UBS with a new price target

Needham initiated coverage on Alkermes Plc with a new price target

$ALKS
Large Ownership Changes

SEC Form SC 13G filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

$ALKS
Financials

Alkermes plc Reports Second Quarter 2025 Financial Results

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Alkermes plc Reports First Quarter 2025 Financial Results

$ALKS
Leadership Updates

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ALKS

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ALKS

$ALKS SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Alkermes plc

SEC Form S-8 filed by Alkermes plc

SEC Form 10-Q filed by Alkermes plc

$ALKS Insider Trading

EVP, CLO, Alkermes, Inc. Gaffin David Joseph converted options into 2,014 units of Ordinary Shares and covered exercise/tax liability with 895 units of Ordinary Shares, increasing direct ownership by 0.55% to 205,374 units (SEC Form 4)

SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

$ALKS Press Releases

Alkermes plc Reports Second Quarter 2025 Financial Results

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Alkermes to Report Second Quarter Financial Results on July 29, 2025

$ALKS Analyst Ratings

Goldman initiated coverage on Alkermes Plc with a new price target

Alkermes Plc upgraded by UBS with a new price target

Needham initiated coverage on Alkermes Plc with a new price target

$ALKS Large Ownership Changes

SEC Form SC 13G filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

$ALKS Financials

Alkermes plc Reports Second Quarter 2025 Financial Results

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Alkermes plc Reports First Quarter 2025 Financial Results

$ALKS Leadership Updates

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Recent Analyst Ratings for
$ALKS

Recent Analyst Ratings for
$ALKS

$ALKS
SEC Filings

$ALKS
Insider Trading

$ALKS
Press Releases

$ALKS
Analyst Ratings

$ALKS
Large Ownership Changes

$ALKS
Financials

$ALKS
Leadership Updates